Biocon Biologics focusing on market share gains of biosimilars in key markets

Biocon Biologics is focused on improving cash flows and increasing market shares of its biosimilar products, particularly in the US and Europe. The company is dealing with rising pricing pressure and delays in key approvals. The integration of Viatris' biosimilar business, acquired for $3.34 billion, has been completed in 120 countries, one year ahead of schedule.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news